Age / Gender: 37 years / Male

Patient ID: 31949
Source: MEDI WHEEL

Referral: SELF

Collection Time: Jan 12, 2024, 01:08 p.m.

Reporting Time: Jan 12, 2024, 05:08 p.m.

Sample ID:

			I
6	684303	357	

Test Description	Value(s)	Reference Range	Unit	
CBC; Complete Blood Count				
Hemoglobin (Hb)*  Method : Cynmeth Photometric Measurement	14.5	13.5 - 18.0	gm/dL	
Erythrocyte (RBC) Count*  Method : Electrical Impedence	5.08	4.7 - 6.0	mil/cu.mm	
Packed Cell Volume (PCV)*  Method : Calculated	41.8	42 - 52	%	
Mean Cell Volume (MCV)*  Method : Electrical Impedence	82.28	78 - 100	fL	
Mean Cell Haemoglobin (MCH)*  Method : Calculated	28.54	27 - 31	pg	
Mean Corpuscular Hb Concn. (MCHC)*  Method : Calculated	34.69	32 - 36	gm/dL	
Red Cell Distribution Width (RDW)*  Method : Electrical Impedence	13.7	11.5 - 14.0	%	
Total Leucocytes (WBC) Count*  Method : Electrical Impedence	6300	4000-10000	cell/cu.mm	
Neutrophils*  Method : VCSn Technology	61	40 - 80	%	
Lymphocytes*  Method : VCSn Technology	31	20 - 40	%	
Monocytes*  Method : VCSn Technology	7	2 - 10	%	
Eosinophils*  Method : VCSn Technology	1	1 - 6	%	
Basophils	0	0 - 1		
Platelet Count*  Method : Electrical Impedence	3.26	1.5 - 4.5	Lakhs/cu.mm	
Mean Platelet Volume (MPV)*  Method : Electrical Impedence	8.1	7.2 - 11.7	fL	

Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by



Age / Gender: 37 years / Male

Patient ID: 31949
Source: MEDI WHEEL

Referral: SELF

Collection Time: Jan 12, 2024, 01:08 p.m.

Reporting Time: Jan 12, 2024, 05:08 p.m.

Sample ID:

668430357

Test Description	Value(s)	Reference Range	Unit
PCT*	0.262	0.2 - 0.5	%
Method : Calculated PDW*	14.7	9.0 - 17.0	%
Method : Calculated	17.7	0.0 17.0	70

Tests done on Automated Three Part Cell Counter. (WBC, RBC, Platelet count by impedance method, colorimetric method for Hemoglobin, WBC differential by flow cytometry using laser technology other parameters are calculated). All Abnormal Haemograms are reviewed confirmed microscopically.

# Esr, Erythrocyte Sedimentation Rate

Esr, Erythrocyte Sedimentation Rate 08 0-10 mm/hr (Westergren)

### Interpretation:

- It indicates presence and intensity of an inflammatory process. It does not diagnose a specific disease. Changes in the ESR are more significant than the abnormal results of a single test.
- It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, bacterial endocarditis, acute rheumatic fever, rheumatoid arthritis, SLE, Hodgkins disease, temporal arteritis and polymyalgia rheumatica.
- It is also increased in pregnancy, multiple myeloma, menstruation, and hypothyroidism.

### **Urine Routine**

Colour*	Yellow		
Volume*	10 ml	-	ml
Transparency (Appearance)*	Clear	Clear	
Reaction (pH)*	6.0	4.5 - 8	
Specific Gravity*	1.020	1.010 - 1.030	

#### Chemical Examination (Automated Dipstick Method) Urine

Urine Glucose*	Negative	Negative
Urine Protein*	Positive (+)	Negative
Urine Ketone*	Negative	Negative

Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by



Age / Gender: 37 years / Male

Patient ID: 31949
Source: MEDI WHEEL

Referral: SELF

Collection Time: Jan 12, 2024, 01:08 p.m.

Reporting Time: Jan 12, 2024, 05:08 p.m.

Sample ID:

	684	303	57	 

Test Description	Value(s)	Reference Range	Unit
Blood*	Positive (Traces)	Negative	
Bilirubin*	Negative	Negative	
Nitrite*	Negative	Negative	
Leucocytes*	Negative	Negative	
Urobilinogen*	Normal	Normal	
Microscopic Examination Urine			
Pus Cells (WBCs)*	5-6	0 - 5	/hpf
Epithelial Cells*	1-2	0 - 4	/hpf
Red blood Cells*	2-3	Absent	/hpf
Crystals*	Absent	Absent	
Cast*	Absent	Absent	
Bacteria*	Absent	Absent	

### **Stool Complete Exam**

### **Blood Group & Rh Type**

**Blood Grouping & Rh Typing** 

"O" + POSITIVE

Method : Forward and Reverse By Tube Method

## Methodology

This is done by forward and reverse grouping by tube Agglutination method.

#### Interpretation

Newborn baby does not produce ABO antibodies until 3 to 6 months of age. So the blood group of the Newborn baby is done by ABO antigen grouping (forward grouping) only, antibody grouping (reverse grouping) is not required. Confirmation of the New-born's blood group is indicated when the A and B antigen expression and the isoagglutinins are fully developed (2–4 years).

Fasting - Glucose

Dr.CH.Deepthi Chandrika M.D. Pathology

Reg.No.APCM/FMR/77174

Approved by



Age / Gender: 37 years / Male

Patient ID: 31949
Source: MEDI WHEEL

Referral: SELF

Collection Time: Jan 12, 2024, 01:08 p.m.

Reporting Time: Jan 12, 2024, 05:08 p.m.

Sample ID:

	2420257	

Test Description	Value(s)	Reference Range	Unit
Glucose Fasting*	85.04	Normal: 70-100	mg/dL
Method : Plasma, Hexokinase		Impaired Fasting Glucose (IFG):	
		101-125	
		Diabetes Mellitus: >125	
Post Prandial Blood Sugar			
Blood Glucose-Post Prandial*	95	80-140	mg/dL
Method : Plasma - P, Hexokinase			
Fasting Urine Sugar			
Fasting Urine Glucose	Negative	Negative	
Post Prandial Urine Sugar			
HBA1C (Glycosylated Haemoglobin)			
Glyco Hb (HbA1C)	6.44	Non-Diabetic: <=5.9	%
Method : EDTA Whole blood,HPLC		Pre Diabetic:6.0-6.4	
		Diabetic: >=6.5	
Estimated Average Glucose :	138.13		mg/dL
Interpretations			

- 1. HbA1C has been endorsed by clinical groups and American Diabetes Association guidelines 2017 for diagnosing diabetes using a cut off point of 6.5%
- 2. Low glycated haemoglobin in a non diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia (especially severe iron deficiency and haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
- 3. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control.

Excellent control-6-7 %

Fair to Good control - 7-8 %

Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by



Age / Gender: 37 years / Male

Patient ID: 31949
Source: MEDI WHEEL

Referral: SELF

**Collection Time :** Jan 12, 2024, 01:08 p.m. **Reporting Time :** Jan 12, 2024, 05:08 p.m.

Sample ID :

Test Description	Value(s)	Reference Range	Unit
Unsatisfactory control – 8 to 10 % Poor Control – More than 10 %			
Thyroid Function Test ( TFT)			
TRI-IODO THYRONINE (T3)  Method : CLIA	1.26	0.60 - 1.81	ng/mL
TOTAL THYROXINE (T4) Method : CLIA	9.84	4.2 - 12.0	ug/dL
THYROID STIMULATING HORMONE (TSH)  Method: CLIA	2.87	0.46 - 8.10 : 1 Yrs - 5 Yrs 0.36 - 5.80 : 6 Yrs - 18 Yrs 0.35 - 5.50 : >18 Yrs Pregnancy Ranges 1st Trimester :0.1 - 2.5 2nd Trimester :0.2 - 3.0 3rd Trimester:0.3 - 3.0	uIU/mL

#### Comments:

IF NOT ON DRUGS SUGGESTED FT3 & FT4 ESTIMATION

#### Please correlate with clinical conditions.

**Note**: Serum T3, T4 and TSH form the three components of thyroid screening panel, useful in diagnosing various disorders of the thyroid gland. Primary Hypothyroidism is accompanied by depressed serum T3 and T4 values and elevated serum TSH levels. Although elevated TSH levels are nearly always indicative of Primary Hypothyroidism, rarely they can from TSH secreting pituitary tumors (Secondary hyperthyroidism)To confirm diagnosis - evaluate FT3 and FT4.

## **Lipid Profile**

Dr.CH.Deepthi Chandrika M.D. Pathology

Reg.No.APCM/FMR/77174

Approved by



Age / Gender: 37 years / Male

Patient ID: 31949

Source: MEDI WHEEL

Referral: SELF

**Collection Time :** Jan 12, 2024, 01:08 p.m. **Reporting Time :** Jan 12, 2024, 05:08 p.m.

Sample ID:



Test Description	Value(s)	Reference Range	Unit
Cholesterol-Total  Method : Serum, Cholesterol oxidase esterase, peroxidase	185.6	Desirable: <= 200 Borderline High: 201-239 High: > 239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.	mg/dL
Triglycerides  Method : Serum, Enzymatic, endpoint	88.89	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
Cholesterol-HDL Direct  Method : Serum, Direct measure-PEG	45.9	<40: Low 40 - 60: Optimal > 60: Desirable	mg/dL
LDL Cholesterol Method : Serum	121.92	Optimal: < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190	mg/dL
Non - HDL Cholesterol, Serum  Method : calculated	139.70	Desirable: < 130 mg/dL Borderline High: 130-159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL	mg/dL
VLDL Cholesterol  Method : calculated	17.78	6 - 38	mg/dL
CHOL/HDL RATIO  Method : calculated	4.04	3.5 - 5.0	ratio
LDL/HDL RATIO  Method : calculated	2.66	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	ratio

Dr.CH.Deepthi Chandrika M.D. Pathology

Reg.No.APCM/FMR/77174

Approved by



Age / Gender: 37 years / Male

Patient ID: 31949 Source: MEDI WHEEL Referral: SELF

Collection Time: Jan 12, 2024, 01:08 p.m. Reporting Time: Jan 12, 2024, 05:08 p.m. Sample ID:

			668430357	
Test Description	Value(s)	Reference Range	Unit	
Note: 8-10 hours fasting sample is required.				
KIDNEY FUNCTION TEST				
Urea *  Method : Serum	19.29	15- 50	mg/dL	
Blood Urea Nitrogen-BUN*  Method : Serum, Urease	9.01	7 - 24	mg/dL	
Uric Acid*  Method : Serum, Uricase/POD	5.19	3.5 - 7.2	mg/dL	
Creatinine*  Method : Serum, Jaffe IDMS	1.18	0.7 - 1.3	mg/dL	
Liver Funtion Test (LFT) with GGT				
Bilirubin - Total  Method : Serum, Jendrassik Grof	1.06	0.3 - 1.2	mg/dL	
Bilirubin - Direct  Method : Serum, Diazotization	0.35	Adults and Children: < 0.5	mg/dL	
Bilirubin - Indirect  Method : Serum, Calculated	0.71	0.1 - 1.0	mg/dL	
SGOT  Method : Serum, UV with P5P, IFCC 37 degree	20.5	< 50	U/L	
SGPT  Method : Serum, UV with P5P, IFCC 37 degree	25.2	< 50	U/L	
Alkaline Phosphatase-ALP  Method : Serum, PNPP, AMP Buffer, IFCC 37 degree	81.0	30-120	U/L	
Total Protein  Method : Serum, Biuret, reagent blank end point	7.87	6.6 - 8.3	g/dL	
Albumin  Method : Serum, Bromcresol purple	4.49	Adults: 3.5 - 5.2	g/dL	
mounda . Octum, bromoreson purple				

Obsepter Dr.CH.Deepthi Chandrika M.D. Pathology Reg.No.APCM/FMR/77174

Approved by



Age / Gender: 37 years / Male

Patient ID: 31949

Source: MEDI WHEEL

Referral: SELF

**Collection Time :** Jan 12, 2024, 01:08 p.m. **Reporting Time :** Jan 12, 2024, 05:08 p.m.

Sample ID :

668430357

Test Description	Value(s)	Reference Range	Unit
Globulin	3.38	1.8 - 3.6	g/dL
Method : Calculated			
A/G Ratio Method : Calculated	1.33	1.2 - 2.2	ratio

\*\*END OF REPORT\*\*

Dr.CH.Deepthi Chandrika M.D. Pathology

Reg.No.APCM/FMR/77174

Approved by

